Bristol-Myers Squibb Aktie

41,35 EUR +0,79 EUR +1,94 %

19:27:52

FSE

47,74 USD -0,72 USD -1,49 %

20:40:41

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.84,05 Mrd. EUR

Div. Rendite4,28%

WKN850501

ISINUS1101221083

SymbolBMY

Bristol-Myers Squibb Aktien News

Sortieren:Datum Meistgelesen

29.07.24BenzingaThis Bristol-Myers Squibb Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

26.07.24MotleyFoolWhy Bristol Myers Squibb Jumped Nearly 10% on Friday

26.07.24MotleyFoolBristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript

26.07.24MotleyFoolBristol Myers Squibb Raises Outlook After Solid Q2 Earnings

26.07.24ZacksBristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates

26.07.24BenzingaBristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast

26.07.24MarketWatchBristol Myers Squibb results beat expectations as newer drugs deliver growth

26.07.24BenzingaBristol-Myers Squibb, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday

22.05.24PR NewswireNeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

29.04.24PR NewswireRepertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

12.04.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

28.03.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

19.03.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

14.12.23PR NewswireTerray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb

28.11.23PR NewswireAvidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology

30.10.23PR NewswireKaryopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory...

06.10.23PR NewswireParadigm and Bristol Myers Squibb collaborate to build a new model for clinical trials

18.09.23PR NewswireSamsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance

28.08.23PR NewswireCellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform

28.06.23PR NewswireK36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic T...

29.11.22PR NewswireEnvisagenics Announces Research Collaboration with Bristol Myers Squibb

10.11.22PR NewswireHealth Canada Approves Camzyos™ (mavacamten capsules) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

09.11.22RSSForm 4 14272

27.10.22PR NewswireObsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

26.10.22RSSForm 8-K 14272

22.09.22RSSStatement of changes in beneficial ownership of securities

23.08.22PR NewswireHealth Canada Approves OPDIVO® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Adult Patients with Resectable Non-Small Cell Lung Cancer

16.08.22RSSTender offer statement by Third Party

09.08.22RSSTender offer statement by Third Party

31.01.20ReutersCORRECTED-UPDATE 1-Bristol-Myers Squibb pulls Opdivo+Yervoy lung application in Europe

16.11.19ReutersUPDATE 2-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

15.11.19ReutersBristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

15.11.19ReutersUPDATE 1-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

15.11.19ReutersBristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug

Bristol-Myers Squibb News

Bristol-Myers Squibb News: auf dieser Seite finden Sie alle Bristol-Myers Squibb News und Nachrichten zur Bristol-Myers Squibb Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Bristol-Myers Squibb News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Bristol-Myers Squibb News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.